S-1 Maintenance Therapy After First-Line Treatment With Nab-Paclitaxel Plus S-1 for Advanced Pancreatic Adenocarcinoma: A Real-World Study

BACKGROUND: In our previous phase II study, nab-paclitaxel plus S-1 (NPS) showed encouraging objective response rate (ORR) as first-line treatment for advanced pancreatic adenocarcinoma (APAC). This study aimed to evaluate the effectiveness and safety of S-1 maintenance after NPS in APAC and to expl...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yan, Han, Quanli, Yan, Huan, Lv, Yao, Yuan, Jing, Li, Jie, Guan, Shasha, Wang, Zhikuan, Huang, Lei, Dai, Guanghai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9141286/
https://www.ncbi.nlm.nih.gov/pubmed/35646689
http://dx.doi.org/10.3389/fonc.2022.865404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9141286/
https://www.ncbi.nlm.nih.gov/pubmed/35646689
http://dx.doi.org/10.3389/fonc.2022.865404

Ejemplares similares